While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination.

Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

With the threat of pharmaceutical tariffs hanging over the biopharmaceutical industry, Roche is the latest addition to a ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...